



Evidence reviews - June 2022

Evidence review

Published: 22 June 2022

www.nice.org.uk

The following documents contain the evidence that was used to develop the recommendations:

- Committee discussion for diagnostic criteria for multiple sclerosis; possible multiple sclerosis; neuromyelitis optica and clinically isolated syndrome
- Information and support for patients (including people who may become pregnant),
 their families and carers
- Coordination of care: the role of MS nurse specialists and other healthcare professionals
- Non-pharmacological management of fatigue
- Appendices for non-pharmacological management of fatigue
- Pharmacological management of fatigue
- Pharmacological management of mobility problems
- Pharmacological management of spasticity
- Non-pharmacological management of pain
- Non-pharmacological management of memory and cognitive problems
- Appendices for non-pharmacological management of memory and cognitive problems
- Pharmacological management of ataxia and tremor

Other supporting evidence

| Evidence reviews – June 2022 | |
|---|--|
| Cost-utility analysis: Fampridine for the treatment of MS mobility Full guideline – October 2014 | |
| | |
| | |
| | |
| | |
| | |